The Central Drugs Standard Control Organization (CDSCO) has canceled the licenses of 18 pharma company for not following the Good Manufacturing Practices (GMP) norms. The companies are from various states across India, including Delhi, Haryana, Uttar Pradesh, Maharashtra, and Telangana.

The decision to cancel the licenses of these companies was taken after a surprise inspection by the CDSCO found that they were not adhering to the GMP guidelines. This is a serious violation, as GMP is essential to ensure that the drugs produced by these companies are of good quality and safe for consumption.

The cancellation of the licenses of these 18 pharma companies will have a significant impact on the pharmaceutical industry, as it will lead to a shortage of drugs produced by these companies. However, it is important to ensure that the drugs produced by these companies are of good quality and safe for consumption, as the health and well-being of the people depend on them.

It is also reported that the CDSCO has initiated legal action against these companies and is taking steps to prevent the sale of their existing stock. The CDSCO has also directed the state drug controllers to take necessary action against these companies.

In conclusion, the cancellation of licenses of these 18 pharma companies highlights the importance of adhering to the GMP guidelines to ensure the safety and quality of drugs produced in India. The CDSCO’s swift action in this regard is commendable and should serve as a warning to other companies to comply with the guidelines.